Mcrae Capital Management Inc. Has $8.38 Million Stock Position in Becton, Dickinson and Company $BDX

Mcrae Capital Management Inc. cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,671 shares of the medical instruments supplier’s stock after selling 6,475 shares during the period. Becton, Dickinson and Company makes up approximately 1.7% of Mcrae Capital Management Inc.’s investment portfolio, making the stock its 22nd largest holding. Mcrae Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $8,384,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Modera Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company by 1.3% in the 2nd quarter. Modera Wealth Management LLC now owns 5,040 shares of the medical instruments supplier’s stock valued at $868,000 after acquiring an additional 63 shares during the last quarter. SouthState Corp increased its stake in Becton, Dickinson and Company by 6.2% in the second quarter. SouthState Corp now owns 4,163 shares of the medical instruments supplier’s stock valued at $717,000 after purchasing an additional 244 shares in the last quarter. Stone House Investment Management LLC raised its holdings in Becton, Dickinson and Company by 3,788.9% in the second quarter. Stone House Investment Management LLC now owns 350 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 341 shares during the period. Anchor Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 6,761.9% during the second quarter. Anchor Capital Advisors LLC now owns 93,802 shares of the medical instruments supplier’s stock worth $16,157,000 after purchasing an additional 92,435 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. grew its holdings in shares of Becton, Dickinson and Company by 4.8% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 105,286 shares of the medical instruments supplier’s stock valued at $18,103,000 after buying an additional 4,775 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $177.44 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average price is $187.07 and its two-hundred day moving average price is $182.55. The company has a market cap of $50.86 billion, a PE ratio of 31.91, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 1,032 shares of company stock worth $193,040. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on BDX shares. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.